Zobrazeno 81 - 90
of 386
pro vyhledávání: '"Pierluigi Porcu"'
Autor:
F. Rotolo, Olivier Dereure, Stéphane Dalle, P. L. Zinzani, Youn H. Kim, Marie Beylot-Barry, H. A Azim, L. Mortier, P L Ortiz-Romero, Martine Bagot, Eric N. Jacobsen, Pierluigi Porcu, A. Cambalia
Publikováno v:
Hematological Oncology. 39
Autor:
Eric D. Jacobsen, Toyotaka Kawamata, G Serbest, Kenji Ishitsuka, Kisato Nosaka, Shigeru Kusumoto, Nobuaki Adachi, Yoshitaka Imaizumi, Satoko Morishima, Kensei Tobinai, Kunihiro Tsukasaki, Dai Maruyama, Koji Izutsu, Kazunobu Kato, P Allen, Pierluigi Porcu, N. Yamauchi, Steve Horwitz, Shinichi Makita, Atae Utsunomiya, Francine M. Foss
Publikováno v:
Hematological Oncology. 39
Autor:
Maarten H. Vermeer, Martine Bagot, Federico Rotolo, Cécile Bonnafous, Hélène Sicard, Anne Marie-Cardine, Hatem A. Azim, Caroline Ram-Wolff, Sean Whittaker, Maxime Battistella, Michael S. Khodadoust, Carine Paturel, Armand Bensussan, Pierluigi Porcu, Basem M. William, Youn H. Kim
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2019, 20 (8), pp.1160-1170. ⟨10.1016/S1470-2045(19)30320-1⟩
Lancet Oncology, Elsevier, 2019, 20 (8), pp.1160-1170. ⟨10.1016/S1470-2045(19)30320-1⟩
Summary Background IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sezary syndrome. We aimed to assess the safety and a
Publikováno v:
Haematologica
Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy
Autor:
Stephen Couban, James R. Cook, Kevin Barton, Pierluigi Porcu, Louis S. Constine, Patrick J. Stiff, Stephen J. Forman, Glenn Mills, Thomas C. Shea, Richard I. Fisher, Douglas A. Stewart, John P. Leonard, Hongli Li, Jonathan W. Friedberg, Brad S. Kahl, Michael LeBlanc, Jane N. Winter, Sonali M. Smith, Zeina Al-Mansour, Lisa M. Rimsza, Deborah Marcellus
Publikováno v:
Leuk Lymphoma
Phase II data suggest a benefit to autotransplantation for aggressive T-NHL in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative
Autor:
Pierluigi Porcu, Maxime Battistella, Andrea Cambalia, Federico Rotolo, Youn H. Kim, Marie Beylot-Barry, Pier Luigi Zinzani, Olivier Dereure, Hélène Moins-Teisserenc, Eric N. Jacobsen, Alejandro A. Gru, Christine Paiva, Pablo L. Ortiz-Romero, Hatem A. Azim, Agnès Boyer-Chammard, Stéphane Dalle, Laurent Mortier, Martine Bagot
Publikováno v:
European Journal of Cancer. 156:S20-S21
Autor:
Adam F. Binder, Pierluigi Porcu
Publikováno v:
Oncology Times. 40:1-17
Autor:
Marco De Dominici, Valentina Minieri, Patrizia Porazzi, Bruno Calabretta, Marja T. Nevalainen, Samanta A. Mariani, Orietta Spinelli, Alessandro Rambaldi, Pierluigi Porcu, Luke F. Peterson
Publikováno v:
Cancer Research. 78:5793-5807
Combining standard cytotoxic chemotherapy with BCR-ABL1 tyrosine kinase inhibitors (TKI) has greatly improved the upfront treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, due to the develo
Autor:
Larisa Geskin, Brigitte Dréno, Athanasios Tsianakas, Steven M. Horwitz, Richard A Cowan, Stacie Hudgens, Mollie Leoni, Lysbeth Floden, Marie Beylot-Barry, Stéphane Dalle, Stephen Dale, Madeleine Duvic, Pierluigi Porcu, Dolores Caballero, Alison J. Moskowitz, Pietro Quaglino, Auris Huen, Fiona Herr, Martine Bagot
Publikováno v:
Clin Lymphoma Myeloma Leuk
Sézary syndrome (SS) and mycosis fungoides (MF), 2 types of cutaneous T-cell lymphoma, cause significant morbidity and adversely affect patients' quality of life (QoL). The present study assessed the QoL measurement changes in patients receiving mog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aabd0a27f1d1b60bae4fc19a10ab671e
http://hdl.handle.net/2318/1815295
http://hdl.handle.net/2318/1815295
Autor:
John L. Wagner, Lindsay Wilde, Neil Palmisiano, Ubaldo E. Martinez-Outschoorn, Pierluigi Porcu, Gina Keiffer, Joanne Filicko-O'Hara, Dolores Grosso, Allison Zibelli, Matthew Carabasi, Neal Flomenberg, Michael Millenson, Onder Alpdogan, Thomas R. Klumpp, Usama Gergis, Amy R. MacKenzie, Adam Binder, Margaret Kasner
Publikováno v:
Blood
Introduction :The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent coronavirus-19 (COVID-19) pandemic has impacted hematologic malignancies (HM) care worldwide. Reported risk factors for severe COVID-19 pre